Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Drug Reactions01:27

Allergic Drug Reactions

1.3K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.3K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

627
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
627
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

4.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.8K
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

3.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.4K
Drug Biotransformation: Overview01:28

Drug Biotransformation: Overview

2.3K
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
2.3K
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids01:19

Phase II Reactions: Sulfation and Conjugation with α-Amino Acids

801
Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
801

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"Drug Reaction with Eosinophilia and Systemic Symptoms" (DRESS): Long-term Outcomes Based on Severity - A Cohort Study.

Acta dermato-venereologica·2026
Same author

Descriptive Analysis of DRESS Reports from EudraVigilance and DRESS Cases from the RegiSCAR-project.

Dermatology (Basel, Switzerland)·2026
Same author

Thyrostatic Drugs and Severe Skin Reactions: A Registry Evaluation Over 20 Years.

Deutsches Arzteblatt international·2026
Same author

Real-World Burden of Generalized Pustular Psoriasis in a French Observational Study: Prevalence, Incidence, Healthcare Resource Utilization, Comorbidities, Treatment Use, and Mortality.

Dermatology and therapy·2026
Same author

Response to the Letter Regarding "Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Induced by Meropenem in a Patient Under Therapy With Avelumab and Subsequent Flare-up".

Journal of investigational allergology & clinical immunology·2026
Same author

Epidermal necrolysis (Stevens-Johnson syndrome/ toxic epidermal necrolysis) as extensive boundary violation: A qualitative study on the illness experience and care needs of survivors in the context of the first German guideline.

PloS one·2025

Related Experiment Video

Updated: Dec 28, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.8K

Bullous Drug Reactions.

Maja Mockenhaupt1

  • 1Dokumentationszentrum schwerer Hautreaktionen (dZh), Department of Dermatology, Medical Center - University of Freiburg, Hauptstrasse 7, DE-79104 Freiburg, Germany. dzh@uniklinik-freiburg.de.

Acta Dermato-Venereologica
|February 11, 2020
PubMed
Summary

Severe bullous drug eruptions, a type of severe cutaneous adverse reaction (SCAR), require prompt recognition and management. Early identification and differentiation from other blistering conditions are crucial for effective patient care.

Keywords:
Stevens-Johnson syndromegeneralized bullous fixed drug eruptiontoxic epidermal necrolysissevere cutaneous adverse reaction

More Related Videos

Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity
10:22

Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity

Published on: September 16, 2011

34.0K
A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo
11:17

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

Published on: August 11, 2018

12.4K

Related Experiment Videos

Last Updated: Dec 28, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.8K
Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity
10:22

Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity

Published on: September 16, 2011

34.0K
A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo
11:17

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

Published on: August 11, 2018

12.4K

Area of Science:

  • Dermatology
  • Clinical Pharmacology

Background:

  • Bullous drug eruptions are infrequent but severe cutaneous adverse reactions (SCAR).
  • These conditions pose significant challenges to patients and physicians.
  • Early recognition and differentiation from other blistering disorders are critical.

Purpose of the Study:

  • To highlight the importance of recognizing severe bullous drug eruptions.
  • To emphasize the need for timely diagnosis and management.
  • To discuss diagnostic procedures and treatment strategies.

Main Methods:

  • Review of clinical presentations and diagnostic challenges.
  • Discussion of differential diagnoses for blistering skin conditions.
  • Outline of management principles including drug withdrawal and supportive care.

Main Results:

  • Early signs may precede obvious blisters and erosions.
  • Accurate diagnosis is essential to differentiate drug-induced from other causes.
  • Management involves identifying and withdrawing causative agents or treating underlying conditions.

Conclusions:

  • Prompt diagnosis and management of severe bullous drug eruptions are vital.
  • Distinguishing drug-induced reactions from other blistering diseases is key.
  • Treatment strategies include drug withdrawal, supportive care, and potentially immunomodulating therapy.